Please use this identifier to cite or link to this item:
|Title:||Dose escalation experience with Ac-225-PSMA-617 in PSMA targeting alpha-radiation therapy of patients with mCRPC|
|Authors:||KRATOCHWIL Clemens; BRUCHERTSEIFER Frank; GIESEL Frederik; APOSTOLIDIS CHRISTOS; HABERKORN Uwe; MORGENSTERN Alfred|
|Citation:||EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING vol. 43 no. S1 p. S51|
|Type:||Articles in periodicals and books|
|Abstract:||Aim: To develop a standard treatment protocol for Ac-225-PSMA-617 PSMA targeting alpha-radiation therapy. Methods: Treatment dose in kBq per kg body-weight (kBq/kgBW) was stepwise increased from 50 kBq/kg (n=2), 100kBq/kgBW (n=2), 150kBq/kgBW (n=2) and 200 kBq/kgBW (n=4). Additionally, a 2-monthly fractionation regime was compared with a 4-monthly administration interval (n=4). Hematological toxicity, clinical exam and patient self-reported side-effects were assessed every 4 weeks, in case of irregular findings every 2 weeks. In addition PSA was also checked every 4 weeks. Results: Severe xerostomia was dose-limiting before hematological toxicity became relevant. 3 patients with 200kBq/kg and 1 patient with 150kBq/kg requested dose reduction. Thus 100kBq/kgBW was defined as standard treatment dose per cycle. 2/4 patients with a 4-monthly treatment interval had PSA-progression before the succeeding cycle, which then also demonstrated also to be less effective than the 2nd cycle during the 2-monthly treatment regime. With doses above or equal to 100 kBq/kgBW per cycle tumor response in regard to a PSA-decline of >50% was demonstrated in about 70% of the treated patients. Conclusions: A standard treatment dose of 100kBq/kgBW administered every two month seems both associated with remarkable anti-tumor activity and tolerability. In our hospital it became the standard treatment activity for the first phase of routinely clinical application as a salvage therapy for mCRPC.|
|JRC Directorate:||Nuclear Safety and Security|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.